TRDA
Entrada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.82
+10.30%Oct 14, 2026, 11:00 UTC
Entrada Therapeutics said the independent Data Monitoring Committee recommended initiating Cohort 3 of the ELEVATE-44-201 study at 18 mg/kg after reviewing safety and pharmacokinetic data from eight Cohort 2 participants.
Source:Sep 10, 2026, 11:00 UTC
Entrada Therapeutics announced the recipients of its 2026 DREAMS Grant Program, awarding two $50,000 grants to support projects addressing healthcare disparities in the Duchenne muscular dystrophy community.
Source:Aug 5, 2026, 00:00 UTC
Entrada Therapeutics reported Q2 2026 financial results with revenue of $0.9 million, a net loss of $42.8 million, and diluted EPS of -$1.01, compared to revenue of $2.0 million and a net loss of $43.1 million in Q2 2025.
Source: